Women's Imaging

Assigns an ACR O-RADS US (v2022) category 0-5 to an ovarian or adnexal lesion from its ultrasound descriptors, returning the associated malignancy risk band and management guidance.

Estimates gestational age from crown-rump length (Robinson 1975), second-trimester biometry (Hadlock 1984 BPD/HC/AC/FL with composite averaging), or last menstrual period, and derives an estimated date of delivery (Naegele's rule).

Maps the ACR BI-RADS 5th-edition final assessment categories (0–6, including the 4A/4B/4C subdivisions) to their published malignancy-likelihood ranges and management recommendations for mammography, ultrasound, and breast MRI.

Assigns the ACR O-RADS MRI score (0–5) to a sonographically indeterminate adnexal lesion from its composition, fluid and lipid content, and the DCE time-intensity curve (or non-DCE early enhancement) of any solid tissue, with the associated malignancy PPV and management pathway.

Computes sonographic estimated fetal weight from standard biometry using the Hadlock 1985 log10 regressions (BPD/AC/FL or HC/AC/FL), and — when gestational age (24–42 weeks) is given — reports the percentage of the expected 50th-percentile weight and an approximate growth percentile from the Hadlock 1991 in-utero weight standard.

Sums the four-quadrant deepest vertical pockets into the amniotic fluid index and classifies fluid volume as oligohydramnios, normal, or polyhydramnios (with severity), cross-checked against the single deepest pocket. Both the SMFM (AFI ≥24 cm) and the traditional (AFI ≥25 cm) polyhydramnios conventions are offered as labeled options.

Scores the five biophysical profile components (nonstress test, fetal breathing, gross body movement, fetal tone, amniotic fluid volume) at 0 or 2 points each and interprets the total out of 10 with standard management guidance.

Applies the ten IOTA Simple Rules — five benign (B1–B5) and five malignant (M1–M5) ultrasound features — to classify an adnexal mass as benign, malignant, or inconclusive, with guidance on second-stage testing for inconclusive masses.

Checklist of accepted sonographic and MRI signs of placenta accreta spectrum plus the major clinical risk pairing (previa after cesarean). Produces a qualitative suspicion tier from the number and type of findings—not a validated numeric score.

Transvaginal cervical length screening for short cervix, plus umbilical and middle cerebral artery pulsatility indices to compute the cerebroplacental ratio (CPR) and flag brain-sparing physiology and raised placental resistance in context of gestational age.

Stages fetal growth restriction I–IV (or classifies as SGA, not FGR) from estimated fetal weight percentile and Doppler findings (uterine and umbilical artery PI, cerebroplacental ratio, ductus venosus, CTG/short-term variation), with the associated monitoring interval and delivery timing from the Barcelona (BCNatal) protocol.

Determines low-dose aspirin eligibility for pre-eclampsia prevention using NICE NG133 and USPSTF/ACOG high- and moderate-risk factor counting, with optional MAP/uterine-artery/biomarker context.

Maps transvaginal cervical length, gestational age, and maternal risk factors to SMFM Consult #70 / ACOG management pathways — vaginal progesterone, cerclage discussion, or surveillance.

Reads nuchal translucency, PAPP-A, and free beta-hCG as a qualitative pattern (reassuring, T21-suggestive, or T18/13-suggestive) rather than a fabricated numeric risk — a genuine patient-specific combined-test risk requires certified FMF/Astraia or laboratory software.